← Leaderboards
Jerri Michelle Rook
Vanderbilt University
$4,711,471
Attributed
$6,388,379
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2009–24$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,388,379 · 5
By mechanism
R01$4,000,023 · 2
UG3$1,585,635 · 1
UH3$650,243 · 1
F32$152,478 · 1
Top collaborators
- P Jeffrey Conn5 shared
- Robert W Gereau5 shared
- Craig Lindsley5 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- P Jeffrey Conn$37,782,937
- Craig Lindsley$38,671,033
- Wasif N Khan$3,221,518
- Lawrence J Marnett$28,791,111
- Graham F Carpenter$8,971,009
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchReceptorSeriesRodent ModelNovel StrategiesIn VivoDoseMetabotropic Glutamate ReceptorsDrug KineticsPre-Clinical ModelPre-ClinicalPropertyGrm5 GeneAdverse EffectsCognitive DeficitsSchizophreniaImpaired CognitionCognitive FunctionAlzheimer&AposBrainAnimal ModelPositron-Emission TomographyBaseHippocampus (Brain)
Grant awards (17)
Muscarinic Receptor Activators as Antipsychotic Agents$502,014
R01 · FY2024 · MH · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$502,014
R01 · FY2023 · MH · contact PI
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics$191,208
UH3 · FY2023 · NS · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$502,014
R01 · FY2022 · MH · contact PI
Novel mGlu5 Negative Allosteric Modulators as First-in-Class Non-Addictive Analgesic Therapeutics$191,208
UH3 · FY2022 · NS · contact PI
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$76,619
UH3 · FY2022 · NS · contact PI
Muscarinic Receptor Activators as Antipsychotic Agents$531,481
R01 · FY2021 · MH · contact PI
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$191,208
UH3 · FY2021 · NS · contact PI
mGlu Allosteric Modulation in Neurodegenerative Diseases$392,500
R01 · FY2020 · AG · contact PI
Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics$1,585,635
UG3 · FY2019 · NS · contact PI
mGlu Allosteric Modulation in Neurodegenerative Diseases$392,500
R01 · FY2019 · AG · contact PI
mGlu Allosteric Modulation in Neurodegenerative Diseases$392,500
R01 · FY2018 · AG · contact PI
mGlu Allosteric Modulation in Neurodegenerative Diseases$392,500
R01 · FY2017 · AG · contact PI
mGlu Allosteric Modulation in Neurodegenerative Diseases$392,500
R01 · FY2016 · AG · contact PI
In Vivo Characterization of mGluR5 Positive Allosteric Modulators$53,942
F32 · FY2012 · MH · contact PI
In Vivo Characterization of mGluR5 Positive Allosteric Modulators$51,326
F32 · FY2011 · MH · contact PI
In Vivo Characterization of mGluR5 Positive Allosteric Modulators$47,210
F32 · FY2009 · MH · contact PI